

RealRate

PHARMACEUTICAL 2021











PHARMACEUTICAL 2021





Intra-Cellular Therapies Inc. Rank 65 of 402

The relative strengths and weaknesses of Intra-Cellular Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intra-Cellular Therapies Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Intra-Cellular Therapies Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 232%, being 185% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	690,904
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	36,853
Liabilities, Non-Current	23,600
Other Assets	24,411
Other Compr. Net Income	352
Other Expenses	1,909
Other Liabilities	0
Other Net Income	4,235
Other Revenues	22,813
Property and Equipment	1,998
Research and Development	65,782
Selling, General and Administrative Expense	186,363

Output Variable	Value in 1000 USD
Assets	717,314
Liabilities	60,454
Expenses	254,054
Revenues	22,813
Stockholders Equity	656,860
Net Income	-227,006
Comprehensive Net Income	-226,830
Economic Capital Ratio	232%

